Home > Insider Trading > Filing (0000947871-12-000426)

Filing Details

Accession Number:: 0000947871-12-000426
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-05-08 16:18:01
Reporting Period:: 2012-05-04

Filing Date:: 2012-05-08
Accepted Time:: 2012-05-08 16:18:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356576	Supernus Pharmaceuticals Inc	SUPN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055949	D Samuel Isaly	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No
1281668	Orbimed Capital Gp Ii Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-05-04	1,668,472	$0.00	1,668,472	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2012-05-04	624,710	$0.00	624,710	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2012-05-04	206,816	$0.00	206,816	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2012-05-04	734,128	$5.00	2,402,600	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2012-05-04	274,873	$5.00	899,583	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2012-05-04	90,999	$5.00	297,815	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2012-05-04	6,673,891	$0.00	1,668,472	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2012-05-04	2,498,842	$0.00	624,710	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2012-05-04	827,627	$0.00	206,816	$0.00

Exercise Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2005-12-22	No	4	C	Indirect
2005-12-22	No	4	C	Indirect
2005-12-22	No	4	C	Indirect

Footnotes

Each share of Series A Convertible Preferred Stock automatically converted into 0.25 shares of Common Stock (together the shares of Series A Convertible Preferred Stock and the shares of Common Stock, the "Shares") without payment of consideration upon the closing of the Issuer's initial public offering. The shares of Series A Convertible Preferred Stock do not have an expiration date.
The Shares reported herein as indirectly beneficially owned by OrbiMed Capital GP II LLC ("GP II"), OrbiMed Advisors LLC ("Advisors") and Samuel D. Isaly ("Isaly") are directly owned by OrbiMed Private Investments II, LP ("OPI II"), OrbiMed Private Investments II (QP), LP ("OPI II QP") and UBS Juniper Crossover Fund, L.L.C. ("Juniper"). Each of GP II, Advisors, and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by OPII and OPI II QP. This Form 4 is being jointly filed by GP II, Advisors and Isaly. The Reporting Persons have designated a representative, currently Michael B. Sheffery, to serve on the Issuer's board of directors.
These Shares are beneficially owned by OPI II. GP II is the general partner of OPI II. Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP II. Advisors and GP II may be deemed to have beneficial ownership of Shares held by OPI II by virtue of such relationships. Isaly, a natural person, may be deemed to have beneficial ownership of such Shares in his capacity as the managing member of, and holder of a controlling interest, in Advisors.
These Shares are beneficially owned by OPI II QP. GP II is the general partner of OPI II QP. Advisors is the managing member of GP II. Advisors and GP II may be deemed to have beneficial ownership of Shares held by OPI II QP by virtue of such relationships. Isaly, a natural person, may be deemed to have beneficial ownership of such Shares in his capacity as the managing member of, and holder of a controlling interest, in Advisors.
These Shares are beneficially owned by Juniper. Advisors manages the portfolio of Juniper and may be deemed to have beneficial ownership of Shares held by Juniper by virtue of that relationship. Isaly, a natural person, may be deemed to have beneficial ownership of such Shares in his capacity as the managing member of, and holder of a controlling interest, in Advisors.
Each of Advisors, GP II and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.